Additionally, while the performance standards organisations mentioned above require blood glucose meter manufacturers to test for the impact of 24 different interfering substances, many current therapeutic approaches are not included5. One substance that manufacturers do not have to test for is sodium-glucose transport protein 2 (SGLT2). Since 2012, a number of SGLT2 inhibitors have come to market for use in diabetes therapy5.
A study investigating the performance of the Accu-Chek blood glucose monitoring systems (Accu-Chek Active, Accu-Chek Aviva, Accu-Chek Guide, Accu-Chek Instant, and Accu-Chek Performa) looked specifically at patients taking one of four SGLT2-inhibtors6.
- Canagliflozin (Invokana®)
- Dapagliflozin (Farxiga®)
- Empagliflozin (Jardiance®)
- Ertugliflozin (Steglatro®)
The results indicated that, based on the acceptable deviation requirements, none of these medications interfered with the performance of the Accu-Chek blood glucose monitoring systems.
Furthermore, Roche ensures detailed interference testing in Accu-Chek blood glucose meters of over 200 substances6,7, including:
- Substances for high blood pressure such as Ramipril & HCT
- Substances for lipid metabolic disorder such as Atorvastatin
- Substances for uric acid disorder such as Allopurinol.
Reliable measurements are the basis of successful diabetes therapy. With Accu-Chek blood glucose monitoring systems, you can feel confident that patients, including those with type 2 diabetes taking SGLT2-inhibitors, can safely and accurately measure their blood glucose with a reliable meter6.